How to Patent in India | Patentability Research Services for Inventions | Idea Protection Services to Foreign Inventors
Call Us: +91 - 9650247494

Pharmaceutical Drug Patent Expirations for 2017

patent attorney for Pharmaceutical Drug Patent Expirations for 2017

Drug Patent Expirations for 2017

List of Top Ten Drug Companies Patent Expirations Through 2017 in United States | Drug Patent Expirations for 2017

Serial Number Drug Company Name Number of  Drug Patent Expirations for 2017
1 NOVO NORDISK INC 35
2 SANOFI AVENTIS US 23
3 NOVARTIS 22
4 JANSSEN PHARMS 21
5 GILEAD SCIENCES INC 21
6 LILLY 16
7 ABBVIE 16
8 MERCK SHARP DOHME 15
9 GILEAD 14
10 JANSSEN PRODS 12
11 NOVARTIS PHARMS CORP 4
12 NOVARTIS PHARM 1

More than 300+ drug patents are about to expire in the year 2017. Major US drug pharmaceutical companies whose drug patents are expiring in 2017 are Novo Nordisk Inc, Sanofi Aventis US, Novartis, Janssen pharms, Gilead sciences, Lilly, Abbvie followed by Merck,  Gilead, and Jassen prods. The following graph provides a list of top ten (10) US drug pharma companies patent expirations through 2017 in USA. Main drug brands NovoLog® (insulin aspart [rDNA origin] injection), Levemir® (insulin detemir [rDNA origin] injection), ELOXATIN® (oxaliplatin), Allegra (fexofenadine), ZORTRESS (Everolimus) and many others are going to expire in the year 2017.

Top Ten Drug Companies Patent Expirations Through 2017 in United States

NOVO NORDISK INC US Drug Patent Expirations by Year

NOVO NORDISK INC US Drug Patent Expirations by year.

The graph provides a list of number of patents expiring for NOVO NORDISK INC in United States from the year 2015 to 2032. 35 drug patent expirations for 2017 and in 2019 around 47 drug patents are expiring. The most number of patents expiring for NOVO NORDISK INC is in 2026. In 2026, forty eight patents are expiring.

NOVO NORDISK INC US Drug Patent Expirations for the year 2017

United States (US) Patent Number Patent Expiry Date Brand Trademark Active Ingredient
US5866538 19 Jun 2017 NOVOLOG MIX 70/30 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 19 Jun 2017 NOVOLOG MIX 70/30 FLEXPEN INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 19 Jun 2017 NOVOLOG MIX 70/30 PENFILL INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG FLEXPEN INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG FLEXTOUCH INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG INNOLET INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG PENFILL INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG MIX 70/30 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG MIX 70/30 FLEXPEN INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG MIX 70/30 PENFILL INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 LEVEMIR INSULIN DETEMIR RECOMBINANT
US5866538 20 Jun 2017 LEVEMIR FLEXPEN INSULIN DETEMIR RECOMBINANT
US5866538 20 Jun 2017 LEVEMIR FLEXTOUCH INSULIN DETEMIR RECOMBINANT
US5866538 20 Jun 2017 LEVEMIR INNOLET INSULIN DETEMIR RECOMBINANT
US5866538 20 Jun 2017 LEVEMIR PENFILL INSULIN DETEMIR RECOMBINANT
US5866538 20 Jun 2017 NOVOLOG MIX 50/50 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 20 Jun 2017 RYZODEG 70/30 INSULIN ASPART; INSULIN DEGLUDEC
US5860946 1 Jul 2017 VAGIFEM ESTRADIOL
US6458924 22 Aug 2017 VICTOZA LIRAGLUTIDE RECOMBINANT
US7235627 22 Aug 2017 VICTOZA LIRAGLUTIDE RECOMBINANT
US6458924 22 Aug 2017 SAXENDA LIRAGLUTIDE RECOMBINANT
US7235627 22 Aug 2017 SAXENDA LIRAGLUTIDE RECOMBINANT
US5866538 *PED 19 Dec 2017 NOVOLOG MIX 70/30 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 *PED 19 Dec 2017 NOVOLOG MIX 70/30 FLEXPEN INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 *PED 19 Dec 2017 NOVOLOG MIX 70/30 PENFILL INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US5866538 *PED 20 Dec 2017 NOVOLOG INSULIN ASPART RECOMBINANT
US5866538 *PED 20 Dec 2017 NOVOLOG FLEXPEN INSULIN ASPART RECOMBINANT
US5866538 *PED 20 Dec 2017 NOVOLOG FLEXTOUCH INSULIN ASPART RECOMBINANT
US5866538 *PED 20 Dec 2017 NOVOLOG INNOLET INSULIN ASPART RECOMBINANT
US5866538 *PED 20 Dec 2017 NOVOLOG PENFILL INSULIN ASPART RECOMBINANT
US5866538 *PED 20 Dec 2017 NOVOLOG MIX 50/50 INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
US8841252 26 Dec 2017 NORDITROPIN SOMATROPIN RECOMBINANT
US8841252 26 Dec 2017 NORDITROPIN FLEXPRO SOMATROPIN RECOMBINANT
US8841252 26 Dec 2017 NORDITROPIN NORDIFLEX SOMATROPIN RECOMBINANT

More than seven drug brands are expiring for NOVO NORDISK INC in United States in 2017. Major US brands are NovoLog®,  Norditropin®, Levemir®, Saxenda, Victoza®, Vagifem® and Ryzodeg. Ryzodeg is a medicine that contains the active substances insulin degludec and insulin aspart. It is available as a solution for injection in a cartridge (100 units/ml) and in a prefilled pen (100 units/ml). Saxenda is a liraglutide [rDNA origin] injection. Saxenda is used for weight-management and obesity. Victoza® is a liraglutide [rDNA origin] injection. Victoza® is an injectable prescription medicine that may improve blood sugar in adults with type 2 diabetes. Levemir® is an insulin detemir (rDNA origin) injection. The long-acting insulin injection is used to control high blood sugar. Moreover, the long-acting insulin like Levemir® works to control blood sugar between meals and when the person is sleeping. Norditropin® is a somatropin [rDNA origin] injection. Norditropin® helps people living with certain growth-related disorders. Vagifem® is a 10 mcg estradiol vaginal tablet available for menopause symptom relief.

SANOFI AVENTIS United States (US) Drug Patent Expirations by Year

SANOFI AVENTIS US Drug Patent Expirations patent attorney

The graph provides a list of number of patents expiring for SANOFI AVENTIS in United States from the year 2015 to 2034. 23 drug patent expirations for 2017 in comparison to 30 drug patents expiring in 2024. The most number of patents expiring for SANOFI AVENTIS is in the year 2024. After 2024, number of drug patents expiring is less than six patents in subsequent years. Five drug patents are expiring in the year 2025, followed by four drug patents in the year 2027, two drug patents expiring in the 2028, 2029,2030 and 2032 respectively.

SANOFI AVENTIS US Drug Patent Expirations for the year 2017

US Patent Number Patent Expiry Date Brand Trademark Active Ingredient
US5420319 *PED 9 Feb 2017 ELOXATIN OXALIPLATIN
US5420319 *PED 9 Feb 2017 ELOXATIN OXALIPLATIN
US6037353 14 Mar 2017 ALLEGRA FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
US6037353 14 Mar 2017 ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 CHILDREN’S ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 CHILDREN’S ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
US6037353 14 Mar 2017 CHILDREN’S ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 CHILDREN’S ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 ALLEGRA FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 CHILDREN’S ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 14 Mar 2017 CHILDREN’S ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 ALLEGRA FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 CHILDREN’S ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 CHILDREN’S ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 CHILDREN’S ALLEGRA ALLERGY FEXOFENADINE HYDROCHLORIDE
US6037353 *PED 14 Sep 2017 CHILDREN’S ALLEGRA HIVES FEXOFENADINE HYDROCHLORIDE

NOVARTIS United States (US) Drug Patent Expirations by Year

NOVARTIS United States (US) Drug Patent Expirations by Year

The graph provides a list of number of patents expiring for NOVARTIS in United States from the year 2015 to 2034. 27 drug patent expirations for 2017 in comparison to 39 drug patents expiring in 2021. The most number of patents expiring for NOVARTIS is in the year 2021. Around 17 drug patents expiring in 2018, followed by 34 drug patents expiring in 2019 and 24 drug patents expiring in 2020. NOVARTIS seems to be leader in drug pharmaceutical industry with a portfolio of numerous granted patents in recent years. The number of drug patents expiring is less than six patents every year after 2028. Five drug patents are expiring in the years 2029, 2030, and 2032 followed by one drug patent in the year 2034 respectively.

NOVARTIS, NOVARTIS PHARMS CORP & NOVARTIS PHARM US Drug Patent Expirations for 2017

US Patent Number Patent Expiry Date Brand Trademark Active Ingredient
US6004973 *PED 12 Jan 2017 ZORTRESS EVEROLIMUS
US6004973 *PED 12 Jan 2017 AFINITOR EVEROLIMUS
US6004973 *PED 12 Jan 2017 AFINITOR DISPERZ EVEROLIMUS
US5922338 *PED 13 Jan 2017 SANDOSTATIN LAR OCTREOTIDE ACETATE
US5922682 *PED 13 Jan 2017 SANDOSTATIN LAR OCTREOTIDE ACETATE
US6025391 10 Apr 2017 MYFORTIC MYCOPHENOLIC ACID
US6172107 10 Apr 2017 MYFORTIC MYCOPHENOLIC ACID
US5972990 *PED 26 Apr 2017 DIOVAN VALSARTAN
US5424295 13 Jun 2017 ARRANON NELARABINE
US6294197 18 Jun 2017 DIOVAN HCT HYDROCHLOROTHIAZIDE; VALSARTAN
US6294197 18 Jun 2017 DIOVAN VALSARTAN
US6294197 18 Jun 2017 EXFORGE AMLODIPINE BESYLATE; VALSARTAN
US6294197 18 Jun 2017 EXFORGE HCT AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
US6596750 24 Jun 2017 EXJADE DEFERASIROX
US6596750 24 Jun 2017 JADENU DEFERASIROX
US6391874 11 Jul 2017 TYKERB LAPATINIB DITOSYLATE
US6828320 11 Jul 2017 TYKERB LAPATINIB DITOSYLATE
US6455518 29 Jul 2017 ZORTRESS EVEROLIMUS
US6239124 11 Aug 2017 ZORTRESS EVEROLIMUS
US6004565 23 Sep 2017 GILENYA FINGOLIMOD
US6641841 14 Nov 2017 STARLIX NATEGLINIDE
US6844008 14 Nov 2017 STARLIX NATEGLINIDE
US6294197 *PED 18 Dec 2017 DIOVAN HCT HYDROCHLOROTHIAZIDE; VALSARTAN
US6294197 *PED 18 Dec 2017 DIOVAN VALSARTAN
US6294197 *PED 18 Dec 2017 EXFORGE AMLODIPINE BESYLATE; VALSARTAN
US6294197 *PED 18 Dec 2017 EXFORGE HCT AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN
US6162802 19 Dec 2017 LOTREL AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

JANSSEN PHARMS United States (US) Drug Patent Expirations by Year

JANSSEN PHARMS United States (US) Drug Patent Expirations by Year

The graph provides a list of number of patents expiring for JANSSEN PHARMS in United States from the year 2015 to 2031. 21 drug patent expirations for 2017 in comparison to 14 drug patents expiring in 2019. The most number of patents expiring for JANSSEN PHARMS is in the year 2017. Around 9 drug patents expiring in 2018, followed by 14 drug patents expiring in 2019 and 7 drug patents expiring in 2024.  The number of drug patents expiring is less than six patents after 2027. Six drug patents are expiring in the year 2027 followed by 3 drug patents in the year 2029 respectively.

JANSSEN PHARMS Drug Patent Expirations for 2017

United States (US) Patent Number Patent Expiry Date Brand Trademark Active Ingredient
US5792477 2 May 2017 RISPERDAL CONSTA RISPERIDONE
US5916598 2 May 2017 RISPERDAL CONSTA RISPERIDONE
US6403114 2 May 2017 RISPERDAL CONSTA RISPERIDONE
US6077843 12 May 2017 INVEGA SUSTENNA PALIPERIDONE PALMITATE
US6077843 12 May 2017 INVEGA TRINZA PALIPERIDONE PALMITATE
US6099863 6 Jun 2017 RAZADYNE GALANTAMINE HYDROBROMIDE
US6358527 6 Jun 2017 RAZADYNE GALANTAMINE HYDROBROMIDE
US6224905 10 Jun 2017 RISPERDAL RISPERIDONE
US6919373 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US6930129 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US8163798 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US8629179 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US9000038 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US9029416 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US9144549 31 Jul 2017 CONCERTA METHYLPHENIDATE HYDROCHLORIDE
US5792477 *PED 2 Nov 2017 RISPERDAL CONSTA RISPERIDONE
US5916598 *PED 2 Nov 2017 RISPERDAL CONSTA RISPERIDONE
US6403114 *PED 2 Nov 2017 RISPERDAL CONSTA RISPERIDONE
US6077843 *PED 12 Nov 2017 INVEGA SUSTENNA PALIPERIDONE PALMITATE
US6077843 *PED 12 Nov 2017 INVEGA TRINZA PALIPERIDONE PALMITATE
US6224905 *PED 10 Dec 2017 RISPERDAL RISPERIDONE

LILLY United States (US) Drug Patent Expirations by Year

LILLY United States (US) Drug Patent Expirations by Year patent attorney

The graph provides a list of number of patents expiring for LILLY in United States from the year 2016 to 2025. 16 drug patent expirations for 2017 in comparison to another 16 drug patents expiring in 2024. The most number of patents expiring for LILLY is in the years 2017 and 2024. Around 3 drug patents expiring in 2018, followed by 4 drug patents expiring in 2019 and 2020. One drug patent is expiring in 2021 and 2022.

LILLY Drug Patent Expirations for 2017

United States (US) Patent Number Patent Expiry Date Brand Trademark Active Ingredient
US5344932 *PED 24 January 2017 ALIMTA PEMETREXED DISODIUM
US6458811 10 Mar 2017 EVISTA RALOXIFENE HYDROCHLORIDE
US6797719 10 Mar 2017 EVISTA RALOXIFENE HYDROCHLORIDE
US6894064 10 Mar 2017 EVISTA RALOXIFENE HYDROCHLORIDE
US8030330 10 Mar 2017 EVISTA RALOXIFENE HYDROCHLORIDE
US5945416 24 Mar 2017 SYMBYAX FLUOXETINE HYDROCHLORIDE; OLANZAPINE
US5658590 *PED 26 May 2017 STRATTERA ATOMOXETINE HYDROCHLORIDE
US5910319 29 May 2017 PROZAC WEEKLY FLUOXETINE HYDROCHLORIDE
US5985322 29 May 2017 PROZAC WEEKLY FLUOXETINE HYDROCHLORIDE
USRE39030 29 May 2017 PROZAC WEEKLY FLUOXETINE HYDROCHLORIDE
US6960577 1 Nov 2017 ZYPREXA OLANZAPINE
US6960577 1 Nov 2017 ZYPREXA ZYDIS OLANZAPINE
US6960577 1 Nov 2017 SYMBYAX FLUOXETINE HYDROCHLORIDE; OLANZAPINE
US5859006 21 Nov 2017 CIALIS TADALAFIL
US5910319 *PED 29 Nov 2017 PROZAC WEEKLY FLUOXETINE HYDROCHLORIDE
US5985322 *PED 29 Nov 2017 PROZAC WEEKLY FLUOXETINE HYDROCHLORIDE

GILEAD SCIENCES INC United States (US) Drug Patent Expirations by Year

GILEAD SCIENCES INC United States (US) Drug Patent Expirations by Year patent attorney

The graph provides a list of number of patents expiring for GILEAD SCIENCES INC in United States from the year 2015 to 2033. 21 drug patent expirations for 2017 in comparison to 22 drug patents expiring in 2021. The most number of patents expiring for GILEAD SCIENCES INC is in the year 2021. 21 drug patents are expiring for the year 2018. Around 8 drug patents expiring in 2022, followed by 11 drug patents expiring in 2028 and 12 drug patents expiring in 2029.  The number of drug patents expiring is 12 for the year 2030, followed by 10 patents drug patents expiring in 2032. One drug patent is expiring in the year 2033 respectively.

GILEAD SCIENCES INC Drug Patent Expirations for 2017

United States (US) Patent Number Patent Expiry Date Brand Trademark Active Ingredient
US5914331 2 July 2017 COMPLERA EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US5914331 2 Jul 2017 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US5914331 2 Jul 2017 GENVOYA COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US5914331 2 Jul 2017 DESCOVY EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
US5914331 2 Jul 2017 ODEFSEY EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
US5922695 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US5935946 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US5977089 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US6043230 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US5922695 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US5935946 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US5977089 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US6043230 25 Jul 2017 VIREAD TENOFOVIR DISOPROXIL FUMARATE
US5922695 25 Jul 2017 COMPLERA EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US5935946 25 Jul 2017 COMPLERA EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US5977089 25 Jul 2017 COMPLERA EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US6043230 25 Jul 2017 COMPLERA EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
US5922695 25 Jul 2017 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US5935946 25 Jul 2017 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US5977089 25 Jul 2017 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
US6043230 25 Jul 2017 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

INTERNATIONAL PATENT SERVICES

Tech Corp Legal has attorney and patent lawyer tie-ups for more than 100 countries. We assist in international patent filing in countries like India, Singapore, Malaysia, United States, Turkey, European Nations, Australia, China, Japan, Brazil, U.A.E, Malaysia, Israel, South Africa, S. Korea, Singapore, Canada, Argentina, Russia. For filing patent internationally contact our experts today.

Freedom to operate search for drug patents and Evidence of Use Search for medicines

Commonly “Freedom to operate” is known as “FTO” in patent fraternity. Freedom to operate is also known as “Clearance” search or “Right to Use” search. This patent service is in depth analysis of legal status of prior art search which involves rigorous claim mapping and analysis.

Why to get Freedom to operate search for drug patents?

Freedom to operate patent search is usually conducted to determine whether a particular action, such as testing or commercializing a drug or medicine, can be done without infringing valid intellectual property rights of others. Freedom to operate is performed country wise or territory wise. IP rights are specific to different jurisdictions, and patent rights can be enforced in country or territory where the patent rights are are secured.

A freedom to operate search examines the patent claims language of the third-party in-force patents and is performed to assess the risk of potential infringement. Freedom to operate search report provides a legal opinion by the patent lawyer on the clearance of products, technologies, or processes. The freedom to operate search helps to analyze the company that whether there is any freedom to operate in that county or not, without infringing any patents. Freedom to operate search is conducted when the company has a product ready to be launched in the market.

An evidence of use (EOU) search is patent to product mapping. In this search the patent claims of considered patent is mapped with product which has been launched or continued after the priority of patent and publication of patent. Our team of proficient patent lawyers and patent attorneys are well-versed in FTO/EOU Searches and provide legal opinion. The flat fee charges quoted by our patent company is highly competitive with present market.

Patent Advocates & Indian IPR Attorneys

Leading IP firm in India with a team of experienced patent strategy consultants who assist startup businesses with patent filing, patent drafting, & protection of trademarks internationally under madrid protocol. Most recommended full service Intellectual Property & Commercial Patent Law firm in India. Direct representation of parties before WIPO and IPO, Coordination and management of Global IP Prosecution and Litigation matters with patent lawyers worldwide, Global IP Strategy and development of Intellectual Assets, Drafting, reviewing and negotiating IP and Technology Agreements (Licensing, Technology Transfer and Collaboration Agreements), Strong patent claim drafting, preparation and prosecution skills for international applications filed before USPTO, EPO, WIPO, UKIPO, MyIPO, IP Australia, & IPOS.